EA202092241A1 - Кристаллическая форма тетрагидрохлорида триэтилентетрамина и ее фармацевтическое применение - Google Patents

Кристаллическая форма тетрагидрохлорида триэтилентетрамина и ее фармацевтическое применение

Info

Publication number
EA202092241A1
EA202092241A1 EA202092241A EA202092241A EA202092241A1 EA 202092241 A1 EA202092241 A1 EA 202092241A1 EA 202092241 A EA202092241 A EA 202092241A EA 202092241 A EA202092241 A EA 202092241A EA 202092241 A1 EA202092241 A1 EA 202092241A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline form
triethylentethramine
tetrahydrochloride
pharmaceutical application
triethylenetetramine tetrachloride
Prior art date
Application number
EA202092241A
Other languages
English (en)
Inventor
Тимоти Джеймс Морли
Ронни Максвелл Лоуренс
Насим Амин
Original Assignee
Орфалан
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62455418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202092241(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Орфалан filed Critical Орфалан
Publication of EA202092241A1 publication Critical patent/EA202092241A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/84—Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящем изобретении описана новая кристаллическая форма тетрахлорида триэтилентетрамина, обладающая улучшенной стабильностью при комнатной температуре по сравнению с известными формами и по сравнению с дихлоридной солью. Новая кристаллическая форма характеризуется наличием пиков в спектре XRPD при 22,9, 25,4, 25,8, 26,6, 34,6 и 35,30,1°2 и сдвигов комбинационного рассеяния 943, 1173, 1527 и 16125 см-1. Кристаллическая форма тетрахлорида триэтилентетрамина подходит для лечения болезни Вильсона. Также предложен способ получения кристаллической формы тетрахлорида триэтилентетрамина, включающий добавление антирастворителя к водному раствору указанного соединения.
EA202092241A 2018-05-04 2019-05-03 Кристаллическая форма тетрагидрохлорида триэтилентетрамина и ее фармацевтическое применение EA202092241A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18290048 2018-05-04
PCT/EP2019/061441 WO2019211464A1 (en) 2018-05-04 2019-05-03 Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use

Publications (1)

Publication Number Publication Date
EA202092241A1 true EA202092241A1 (ru) 2021-04-01

Family

ID=62455418

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092241A EA202092241A1 (ru) 2018-05-04 2019-05-03 Кристаллическая форма тетрагидрохлорида триэтилентетрамина и ее фармацевтическое применение

Country Status (17)

Country Link
US (5) US10988436B2 (ru)
EP (1) EP3652145A1 (ru)
JP (1) JP2021531322A (ru)
KR (1) KR20210005270A (ru)
CN (3) CN119306616A (ru)
AR (1) AR115080A1 (ru)
AU (2) AU2019263969B2 (ru)
CA (1) CA3096423A1 (ru)
CO (1) CO2020013806A2 (ru)
DE (1) DE19724752T1 (ru)
EA (1) EA202092241A1 (ru)
ES (1) ES2769049T1 (ru)
MA (2) MA51919A1 (ru)
SA (1) SA520420467B1 (ru)
SG (1) SG11202010785UA (ru)
TW (1) TW202002956A (ru)
WO (1) WO2019211464A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210005270A (ko) * 2018-05-04 2021-01-13 오르파란 트리에틸렌테트라민 테트라클로라이드의 결정형 및 이의 약제학적 용도
KR102489293B1 (ko) * 2020-10-15 2023-01-17 (주) 에프엔지리서치 공업용 등급의 트리에틸렌테트라민의 고순도 정제 방법
AR125456A1 (es) 2021-04-26 2023-07-19 Orphalan S A Control de la concentración de cobre no ligado a la ceruloplasmina
TWI819502B (zh) 2022-02-23 2023-10-21 裕捷股份有限公司 一種三伸乙基四胺四氫氯化物及其製備方法與組合物
CN116675607A (zh) * 2022-02-23 2023-09-01 裕捷股份有限公司 一种三亚乙基四胺四氢氯化物及其制备方法与组合物
WO2024018394A1 (en) * 2022-07-19 2024-01-25 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of crystalline form a of n, n'-bis(2-aminoethyl)-1,2-ethanediamine tetrahydrochloride
EP4487839A1 (en) 2023-07-03 2025-01-08 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical dosage form comprising trientine tetrahydrochloride, and method for preparing the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1078731A (en) 1976-12-16 1980-06-03 Charles E. Frosst And Co. Skeletal imaging kit utilizing triethylene tetramine hexa (methylene phosphonic acid)
CS197093B1 (cs) * 1978-06-16 1980-04-30 Ivo Kuhr Způsob přípravy čistého dihydrochloridu triethylentetraminu
DE19724752A1 (de) 1997-04-24 1998-11-05 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von Entzündungen und Wunden der Haut
EP1075254A2 (en) 1998-04-03 2001-02-14 Theodore Toney Ilenchuk The use of polyamines in the treatment of dermatological symptoms
JP4369003B2 (ja) 2000-02-23 2009-11-18 ハリマ化成株式会社 ハンダ付け用フラックス
DK1487431T3 (da) 2002-03-08 2012-08-20 Philera New Zealand Ltd Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl
WO2003075910A1 (en) 2002-03-08 2003-09-18 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
WO2004017957A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
NZ545724A (en) 2003-03-18 2007-11-30 Protemix Corp Ltd Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure
PT1778618E (pt) 2004-07-19 2014-03-04 Philera New Zealand Ltd Síntese de trietilenotetraminas
CN105753719B (zh) * 2014-12-17 2019-06-21 四川科瑞德凯华制药有限公司 一种盐酸曲恩汀化合物
JP6326477B2 (ja) 2015-12-25 2018-05-16 三洋化成工業株式会社 高分子凝集剤
KR20210005270A (ko) * 2018-05-04 2021-01-13 오르파란 트리에틸렌테트라민 테트라클로라이드의 결정형 및 이의 약제학적 용도
WO2020006027A1 (en) 2018-06-29 2020-01-02 Sharp Laboratories Of America, Inc. Ultra-reliability design for physical uplink control channel (pucch) in 5th generation (5g) new radio (nr)
CN109076617B (zh) 2018-07-25 2022-08-19 北京小米移动软件有限公司 Mtc系统的随机接入方法、装置及存储介质
TWI819502B (zh) 2022-02-23 2023-10-21 裕捷股份有限公司 一種三伸乙基四胺四氫氯化物及其製備方法與組合物

Also Published As

Publication number Publication date
US11117855B2 (en) 2021-09-14
CN111479798A (zh) 2020-07-31
US20200392068A1 (en) 2020-12-17
CO2020013806A2 (es) 2021-01-29
ES2769049T1 (es) 2020-06-24
US20210163398A1 (en) 2021-06-03
CN119306616A (zh) 2025-01-14
US10988436B2 (en) 2021-04-27
US20210188761A1 (en) 2021-06-24
US11072577B2 (en) 2021-07-27
BR112020018451A2 (pt) 2020-12-29
TW202002956A (zh) 2020-01-16
SA520420467B1 (ar) 2024-04-28
JP2021531322A (ja) 2021-11-18
US20240360071A1 (en) 2024-10-31
DE19724752T1 (de) 2020-07-09
SG11202010785UA (en) 2020-11-27
AR115080A1 (es) 2020-11-25
WO2019211464A1 (en) 2019-11-07
EP3652145A1 (en) 2020-05-20
MA51919A1 (fr) 2021-11-30
CN114394904A (zh) 2022-04-26
CA3096423A1 (en) 2019-11-07
MA58726A1 (fr) 2023-09-27
AU2019263969B2 (en) 2024-08-01
KR20210005270A (ko) 2021-01-13
AU2019263969A1 (en) 2020-10-22
US20220169594A1 (en) 2022-06-02
AU2024227767A1 (en) 2024-11-21
CN111479798B (zh) 2024-11-01

Similar Documents

Publication Publication Date Title
EA202092241A1 (ru) Кристаллическая форма тетрагидрохлорида триэтилентетрамина и ее фармацевтическое применение
CY1125051T1 (el) Συντηγμενη ενωση αναστολεα jak ιμιδαζο-πιπεριδινης
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
CY1123353T1 (el) Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA201690458A1 (ru) Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
PE20211548A1 (es) Compuesto de triazina y su uso para fines medicos
MD3672965T2 (ro) Compusi ai pirimidinei ca inhibitori ai kinazei JAK
EA201691071A1 (ru) Фенилтриазолопиридиновые соединения
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
WO2014151630A3 (en) Compounds and compositions for the treatment of parasitic diseases
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
PH12016501198A1 (en) Compounds and compositions for the treatment of parasitic diseases
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса
EA202091588A1 (ru) Способ получения аминопиримидина и его промежуточных продуктов
EA202092558A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА ИНГИБИТОРА c-MET, ЕГО СОЛЕВАЯ ФОРМА И СПОСОБ ИХ ПОЛУЧЕНИЯ
EA202192760A1 (ru) Трициклические соединения
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.